Showing 661 - 680 results of 101,118 for search '(( 12 mg decrease ) OR ( 5 ((((nn decrease) OR (a decrease))) OR (teer decrease)) ))', query time: 1.32s Refine Results
  1. 661
  2. 662
  3. 663

    DataSheet_2_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx by Qinggan Ni (14835463)

    Published 2023
    “…Background<p>It has been established that the scavenger receptor class A member 5 (SCARA5) functions as a tumor suppressor gene in various cancer types. …”
  4. 664

    DataSheet_3_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx by Qinggan Ni (14835463)

    Published 2023
    “…Background<p>It has been established that the scavenger receptor class A member 5 (SCARA5) functions as a tumor suppressor gene in various cancer types. …”
  5. 665
  6. 666
  7. 667

    DataSheet_1_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx by Qinggan Ni (14835463)

    Published 2023
    “…Background<p>It has been established that the scavenger receptor class A member 5 (SCARA5) functions as a tumor suppressor gene in various cancer types. …”
  8. 668
  9. 669
  10. 670
  11. 671

    S5 Table - by Mohamad Karaky (8910497)

    Published 2022
    Subjects:
  12. 672
  13. 673
  14. 674
  15. 675
  16. 676
  17. 677
  18. 678

    A Dissolved Oxygen Threshold for Shifts in Bacterial Community Structure in a Seasonally Hypoxic Estuary by Rachel L. Spietz (782905)

    Published 2015
    “…Bacterial community composition across all samples was also strongly associated with the dissolved oxygen gradient, and significant changes in bacterial community composition occurred at a dissolved oxygen concentration between 5.18 and 7.12 mg O<sub>2</sub> L<sup>-1</sup>. …”
  19. 679

    Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study by Winfried M. Amoaku (748780)

    Published 2015
    “…<div><p>The Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (REPAIR) trial was a prospective study exploring the efficacy and safety of intravitreal ranibizumab 0.5 mg using an individualized treatment regimen over 12 months. …”
  20. 680